Article
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2020
Yang Shuo, Mao Shiqi, Li Xuefei, Zhao Chao, Liu Qian, Yu Xiaofei, Wang Yan, Liu Yiwei, Pan Yingying, Wang Chunyan, Gao Guanghui, Li Wei, Xiong Anwen, Chen Bin, Sun Hui, He Yayi, Wu Fengying, Chen Xiaoxia, Su Chunxia, Ren Shengxiang, Zhou Caicun
Abstract excerpt
OBJECTIVES: Advanced non-small cell lung cancer (NSCLC) patients harboring non-resistant uncommon epidermal growth factor receptor (EGFR) mutations have stepped into the era of targeted therapy. This study aimed to investigate the incidence of acquired T790M mutation and their outcome to subsequent osimertinib in patients of advanced NSCLC harboring uncommon EGFR mutations. PATIENTS AND METHODS: Patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.